Have a feature idea you'd love to see implemented?
Let us know!
AVDL Avadel Pharmaceuticals Plc
Price (delayed)
$11.66
Market cap
$1.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.76
Enterprise value
$1.13B
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime
Highlights
Avadel Pharmaceuticals's EPS has surged by 65% YoY and by 33% QoQ
Avadel Pharmaceuticals's net income has soared by 54% YoY and by 32% from the previous quarter
The company's equity fell by 32% YoY but it rose by 6% QoQ
AVDL's quick ratio is down by 18% year-on-year but it is up by 2.6% since the previous quarter
AVDL's gross margin is down by 6% year-on-year and by 2.9% since the previous quarter
Key stats
What are the main financial stats of AVDL
Market
Valuations
Earnings
Shares outstanding
96.36M
Market cap
$1.12B
Enterprise value
$1.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
15.03
Price to sales (P/S)
8.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
Revenue
$138.16M
EBIT
-$62.52M
EBITDA
-$60.53M
Free cash flow
-$82.81M
Per share
Balance sheet
Liquidity
EPS
-$0.76
Free cash flow per share
-$0.86
Book value per share
$0.78
Revenue per share
$1.43
TBVPS
$1.47
Total assets
$158.25M
Total liabilities
$83.59M
Debt
$36.38M
Equity
$74.66M
Working capital
$84.48M
Debt to equity
0.49
Current ratio
2.97
Quick ratio
2.41
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
-43.8%
Gross margin
91.9%
Net margin
-52.5%
Operating margin
-46.3%
Return on assets
-44.8%
Return on equity
-93.3%
Return on invested capital
-58.1%
Return on capital employed
-54.1%
Return on sales
-45.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVDL stock price
How has the Avadel Pharmaceuticals stock price performed over time
Intraday
8.47%
1 week
0.6%
1 month
-13.11%
1 year
N/A
YTD
N/A
QTD
-11.09%
Financial performance
How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$138.16M
Gross profit
$127M
Operating income
-$64M
Net income
-$72.58M
Gross margin
91.9%
Net margin
-52.5%
The net margin has surged by 97% year-on-year and by 53% since the previous quarter
AVDL's operating margin has soared by 97% YoY and by 55% QoQ
Avadel Pharmaceuticals's net income has soared by 54% YoY and by 32% from the previous quarter
The company's operating income has surged by 53% YoY and by 35% QoQ
Growth
What is Avadel Pharmaceuticals's growth rate over time
Valuation
What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.03
P/S
8.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
Avadel Pharmaceuticals's EPS has surged by 65% YoY and by 33% QoQ
The company's equity fell by 32% YoY but it rose by 6% QoQ
The stock's price to book (P/B) is 14% less than its last 4 quarters average of 17.5
The price to sales (P/S) is 65% lower than the last 4 quarters average of 23.0
The revenue has grown by 45% from the previous quarter
Efficiency
How efficient is Avadel Pharmaceuticals business performance
Avadel Pharmaceuticals's return on sales has surged by 97% YoY and by 56% QoQ
The ROE has soared by 72% YoY and by 24% from the previous quarter
The ROIC has soared by 58% YoY and by 31% from the previous quarter
AVDL's return on assets has surged by 52% year-on-year and by 27% since the previous quarter
Dividends
What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVDL.
Financial health
How did Avadel Pharmaceuticals financials performed over time
The total assets is 89% more than the total liabilities
The total assets has contracted by 22% YoY
AVDL's quick ratio is down by 18% year-on-year but it is up by 2.6% since the previous quarter
The debt is 51% smaller than the equity
The debt has declined by 34% year-on-year and by 3.4% since the previous quarter
The company's equity fell by 32% YoY but it rose by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.